Efficacy of cognitive therapy and behavior therapy for menopausal symptoms: a systematic review and meta-analysis

2022 ◽  
pp. 1-13
Author(s):  
Mengfei Ye ◽  
Mengna Shou ◽  
Jian Zhang ◽  
Baiqi Hu ◽  
Chunyan Liu ◽  
...  
Keyword(s):  
Cognitive Therapy ◽  
Behavior Therapy ◽  
Treatment Guidelines ◽  
Psychological Treatment ◽  
Menopausal Symptoms ◽  
Cochrane Library ◽  
Control Groups ◽  
Natural Menopause ◽  
And Behavior

Abstract Background T long-term effects of cognitive therapy and behavior therapy (CTBT) for menopausal symptoms are unknown, and whether the effects are different between natural menopause and treatment-induced menopause are currently unclear. Therefore, we sought to conduct an accurate estimate of the efficacy of CTBT for menopausal symptoms. Methods We conducted searches of Cochrane Library, EMBASE, PsycINFO, PubMed, and Web of Science databases for studies from 1 January 1977 to 1 November 2021. Randomized controlled trials (RCTs) comparing intervention groups to control groups for menopausal symptoms were included. Hedge's g was used as the standardized between-group effect size with a random-effects model. Results We included 14 RCTs comprising 1618 patients with a mean sample size of 116. CTBT significantly outperformed control groups in terms of reducing hot flushes [g = 0.39, 95% confidence interval (CI) 0.23–0.55, I2 = 45], night sweats, depression (g = 0.50, 95% CI 0.34–0.66, I2 = 51), anxiety (g = 0.38, 95% CI 0.23–0.54, I2 = 49), fatigue, and quality of life. Egger's test indicated no publication bias. Conclusions CTBT is an effective psychological treatment for menopausal symptoms, with predominantly small to moderate effects. The efficacy is sustained long-term, although it declines somewhat over time. The efficacy was stronger for natural menopause symptoms, such as vasomotor symptoms, than for treatment-induced menopause symptoms. These findings provide support for treatment guidelines recommending CTBT as a treatment option for menopausal symptoms.

EFFECTIVNESS OF SPECIFIC MOBILE HEALTH APPLICATIONS (mHEALTH-APPS)in GESTATIONAL DIABTETES MELLITUS: A SYSTEMATIC REVIEW (Preprint)

2020 ◽  
Author(s):  
Claudia Eberle ◽  
Maxine Löhnert
Keyword(s):  
Mobile Health ◽  
Cochrane Library ◽  
Clinical Parameters ◽  
Control Groups ◽  
Manual Search ◽  
Mobile Health Applications ◽  
Short And Long Term ◽  
Mhealth Apps ◽  
Health Applications

BACKGROUND Gestational diabetes mellitus (GDM) emerges worldwide and is closely associated with short- and long-term health issues in women and their offspring, such as pregnancy and birth complications respectively comorbidities, Type 2 Diabetes (T2D), Metabolic Syndrome (MetS) as well as cardiovascular disease (CD). Against this background mobile health applications (mHealth-Apps) do open up new possibilities to improve the management of GDM clearly. OBJECTIVE Since there is – to our knowledge – no systematic literature review published, which focusses on the effectiveness of specific mHealth-Apps on clinical health-related short and long-term outcomes of mother and child, we conducted these much-needed analyses. METHODS Data sources: A systematic literature search in Medline (Pubmed), Cochrane Library, Embase, CINAHL and Web of Science was performed including full text publications since 2008 up to date. An additional manual search in references and Google Scholar was conducted subsequently. Study Eligibility Criteria: Women diagnosed with GDM using specific mHealth-Apps during pregnancy compared to control groups, which met main clinical parameters and outcomes in GDM management as well as maternity and offspring care. Study appraisal and synthesis methods: Study quality was assessed and rated “strong”, “moderate” or “weak” by using the Effective Public Health Practice Project (EPHPP) tool. Study results were strongly categorized by outcomes; an additional qualitative summary was assessed. Study selection: Overall, n= 114 studies were analyzed, n= 46 duplicates were removed, n=5 studies met the eligible criteria and n=1 study was assessed by manual search subsequently. In total, n=6 publications, analyzing n=408 GDM patients in the interventional and n=405 women diagnosed with GDM in the control groups, were included. These studies were divided into n=5 two-arm randomized controlled trials (RCT) and n=1 controlled clinical trial (CCT). RESULTS Distinct improvements in clinical parameters and outcomes, such as fasting blood glucoses (FBG), 2-hour postprandial blood glucoses (PBG), off target blood glucose measurements (OTBG), delivery modes and patient compliance were analyzed in GDM patients using specific mHealth-Apps compared to matched control groups. CONCLUSIONS mHealth-Apps clearly improve clinical outcomes in management of GDM effectively. More studies need to be done more in detail.

Current Issues in Behavior and Cognitive Therapy for Obsessive-Compulsive Disorder

CNS Spectrums ◽  
1996 ◽  
Vol 1 (1) ◽  
pp. 47-54 ◽  
Author(s):  
Fugen Neziroglu ◽  
Jonathan Hoffman ◽  
Jose A. Yaryura-Tobias ◽  
David Veale ◽  
Jean Cottraux
Keyword(s):  
Cognitive Therapy ◽  
Obsessive Compulsive Disorder ◽  
Behavior Therapy ◽  
Primary Care Physicians ◽  
Psychological Treatment ◽  
Medication Compliance ◽  
Rational Emotive Behavior Therapy ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Complex Forms

AbstractExposure and response prevention (ERP), a form of behavior therapy, is widely recognized as the most effective psychological treatment for obsessive-compulsive disorder (OCD). Cognitive therapy (meaning rational emotive behavior therapy [REBT], or the Salkovskis model for this article) has received increased attention as an effective method for OCD treatment. These methods have renewed hope for patients suffering with what had long been thought to be a treatment refractory condition. Yet many important issues require further discussion and investigation. At the Second International Conference on OCD, which was held in Guadeloupe, February 14–16, 1996, the following issues were highlighted:1. Which psychotherapies are effective in the treatment of OCD?2. What psychological strategies may be used to increase patient motivation during treatment?3. Are relapse prevention strategies necessary after improvement?4. How do economic factors affect the use of behavior therapy? How is OCD treatment uniform or varying from specialty providers to mental health generalists to primary care physicians? How do self-administered and therapist-administered ERP compare?5. How does the efficacy of ERP or cognitive therapy and pharmacotherapy (either alone or in combination) compare?6. Is ERP effective for complex forms of OCD?7. In OCD treatment, is medication compliance improved if ERP or cognitive therapy is also used, and vice versa? How does this affect relapse rates? In addition, can doses of medications be lowered with the addition of ERP or cognitive therapy?8. What is known about the brain function and biological changes associated with ERP and cognitive therapy?

scholarly journals Comparing internet-delivered cognitive therapy and behavior therapy with telephone support for insomnia disorder: a randomized controlled trial

SLEEP ◽  
2019 ◽  
Vol 43 (2) ◽  
Author(s):  
Rikard Sunnhed ◽  
Hugo Hesser ◽  
Gerhard Andersson ◽  
Per Carlbring ◽  
Charles M Morin ◽  
...  
Keyword(s):  
Adverse Events ◽  
Cognitive Therapy ◽  
Behavior Therapy ◽  
Controlled Trial ◽  
Sleep Onset ◽  
Sleep Onset Latency ◽  
Unique Contribution ◽  
Telephone Support ◽  
Insomnia Disorder ◽  
And Behavior

Abstract Study Objectives Our aim was to compare the effects of Internet-delivered cognitive therapy (CT) and behavior therapy (BT) against a waitlist (WL) condition to better understand their unique contribution in the treatment of insomnia. Methods Two hundred and nineteen participants with insomnia disorder were randomized to CT (n = 72), BT (n = 73), or WL (n = 74). The treatment arms consisted of 10 weekly internet-delivered modules with 15 min of telephone support per week. At pre, post, and follow-up, participants completed measures of insomnia severity, sleep diaries, functional impairment, anxiety, depression, quality of life, adverse events, satisfaction and perception of content, workload, and activity in treatment. Measures of completed exercises, modules, therapist support, and platform logins were also measured at posttreatment. Results Moderate to large effect sizes for both CT and BT outperformed the WL on the majority of outcomes, with significant differences in favor of both therapy groups. Both treatment groups had significantly larger proportion of treatment remitters (CT: 35.8%, BT: 40%, WL: 2.7%) and responders (CT: 74.6%, BT 58.6%, WL: 10.8%) compared to the WL at posttreatment. There were no significant differences between the two therapy groups in terms of outcomes, except for sleep onset latency in favor of BT (6 min difference at posttreatment) and adverse events in favor of CT (CT 14.1% vs BT 43.2%). Conclusions This study indicates that both Internet-delivered CT and BT are effective as stand-alone therapies for insomnia disorder. Results highlight the need for examining which therapy and subcomponents that are necessary for change. ClinicalTrials.gov Identifier NCT02984670

Sign in / Sign up

Export Citation Format

Share Document